Selected article for: "bind motif and RBM bind motif"
Author: Li, Jianhua; Wang, Ping; Tracey, Kevin J.; Wang, Haichao
Title: Possible inhibition of GM-CSF production by SARS-CoV-2 spike-based vaccines
  • Cord-id: 3b6mvpo7
  • Document date: 2021_5_22
    • ID: 3b6mvpo7
    Snippet: A SARS-like coronavirus 2 (SARS-CoV-2) has caused a pandemic Coronavirus Disease 2019 (COVID-19) that killed more than 3.3 million people worldwide. Like the SARS-CoV, SARS-CoV-2 also employs a receptor-binding motif (RBM) of its spike protein to bind a host receptor, the angiotensin-converting enzyme 2 (ACE2), to gain entry. Currently, several mRNA or adenoviral vaccines encoding for the spike protein of SARS-CoV-2 are being used to boost antibodies capable of inhibiting spike-ACE2 interaction
    Document: A SARS-like coronavirus 2 (SARS-CoV-2) has caused a pandemic Coronavirus Disease 2019 (COVID-19) that killed more than 3.3 million people worldwide. Like the SARS-CoV, SARS-CoV-2 also employs a receptor-binding motif (RBM) of its spike protein to bind a host receptor, the angiotensin-converting enzyme 2 (ACE2), to gain entry. Currently, several mRNA or adenoviral vaccines encoding for the spike protein of SARS-CoV-2 are being used to boost antibodies capable of inhibiting spike-ACE2 interaction and viral entry. However, recent evidence has also suggested an anti-inflammatory effect of spike-reactive antibodies, suggesting that some SARS-CoV-2 spike-based vaccines may elicit protective antibodies capable of inhibiting GM-CSF production and COVID-19 progression.

    Search related documents:
    Co phrase search for related documents
    • activation excessive infiltration and acute respiratory syndrome: 1
    • acute ards respiratory distress syndrome and long duration: 1, 2, 3, 4
    • acute ards respiratory distress syndrome and macrophage inflammatory: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20
    • acute respiratory syndrome and adenoviral mrna: 1, 2, 3, 4, 5, 6
    • acute respiratory syndrome and adenoviral mrna vaccine: 1, 2
    • acute respiratory syndrome and adenoviral vaccine: 1, 2, 3, 4, 5, 6, 7, 8
    • acute respiratory syndrome and long duration: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory syndrome and mabs efficacy: 1
    • acute respiratory syndrome and mabs monoclonal antibody: 1, 2, 3, 4, 5, 6, 7
    • acute respiratory syndrome and macrophage inflammatory: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25